Oppenheimer Downgrades aTyr Pharma to Perform
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh has downgraded aTyr Pharma (NASDAQ:LIFE) from Outperform to Perform.

July 05, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
aTyr Pharma has been downgraded from Outperform to Perform by Oppenheimer analyst Hartaj Singh.
Analyst ratings often have a direct impact on a company's stock price. A downgrade from Outperform to Perform suggests that the analyst believes the company's stock will not outperform the market in the near future. This could lead to a decrease in the stock's price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100